In recent years, the prices charged for specialty drugs have become a source of concern for many policymakers. Such drugs typically treat chronic, complex, or rare conditions, frequently have high prices, and may require special handling or patient monitoring. They accounted for a growing share of total net drug spending from 2010 to 2015 in both Medicare’s prescription drug benefit (Part D) and Medicaid. The net prices paid for specialty drugs are much higher in Medicare Part D than in Medicaid, and net spending on such drugs grew much faster in Medicare Part D than in Medicaid.
MAJOR RECURRING REPORTSView All
- Answers to Questions for the Record Following a Hearing on CBO’s Appropriation Request for Fiscal Year 2020 Conducted by the Subcommittee on the Legislative Branch, House Committee on Appropriations
- Answers to Questions for the Record Following a Hearing Conducted by the House Committee on the Budget on The Budget and Economic Outlook: 2019 to 2029